IGROV-1 Cells

The IGROV-1 cell line is a human ovarian adenocarcinoma cell line extensively utilized in research, particularly in studies involving ovarian cancer. Derived from an ovarian carcinoma, IGROV-1 cells are known for their utility in modeling epithelial ovarian cancer (EOC), which accounts for a majority of ovarian malignancies. This cell line has been employed in various contexts, including evaluating drug responses and mechanisms underlying drug resistance. For example, IGROV-1 has been instrumental in testing the efficacy of targeted therapies, such as the folate receptor alpha-targeting antibody-drug conjugate mirvetuximab soravtansine (IMGN853). This ADC showed promising results by synergizing with chemotherapeutics like carboplatin and doxorubicin, enhancing antitumor efficacy through DNA damage and cell cycle arrest in preclinical models. In addition to its role in cancer research, IGROV-1 has been characterized as a model for viral infection studies. Recent work highlighted its susceptibility to SARS-CoV-2, leveraging its expression of ACE2 to support viral replication. IGROV-1 was shown to mount a robust innate immune response upon infection, similar to primary human nasal epithelial cells, indicating its potential for serological assays, antiviral drug testing, and isolation of viral variants from patient samples. This cell line is considered advantageous for research due to its effective replication of viruses compared to traditional models like Vero cells, which can lead to adaptive mutations. Overall, IGROV-1 cells serve as a valuable model in both oncology and virology, supporting studies of tumor biology, drug resistance, and viral pathogenesis. Their relevance in drug synergy experiments and their compatibility with antiviral research underscore their versatility and importance in the field.